Outcomes | cg25365794 | cg08862778 |
---|---|---|
HR (95% CI)* | HR (95% CI)* | |
Overall incident cancer# | ||
Tertile 1 | Ref. | Ref. |
Tertile 2 | 0.77 (0.59, 1.01) | 0.93 (0.71, 1.21) |
Tertile 3 | 0.90 (0.68, 1.18) | 0.84 (0.62, 1.12) |
Increase per 1 SD | 0.98 (0.87, 1.10) | 0.99 (0.87, 1.12) |
Incident lung cancer† | ||
Tertile 1 | Ref. | Ref. |
Tertile 2 | 0.73 (0.46, 1.16) | 0.90 (0.57, 1.41) |
Tertile 3 | 0.78 (0.48, 1.27) | 0.67 (0.40, 1.11) |
Increase per 1 SD | 0.81 (0.66, 0.99) | 0.94 (0.77, 1.15) |
Incident colorectal cancer† | ||
Tertile 1 | Ref. | Ref. |
Tertile 2 | 0.72 (0.43, 1.19) | 1.07 (0.65, 1.76) |
Tertile 3 | 0.83 (0.50, 1.40) | 1.46 (0.88, 2.44) |
Increase per 1 SD | 0.98 (0.79, 1.21) | 1.16 (0.96, 1.41) |
Incident breast cancer‡ (in female participants) | ||
Tertile 1 | Ref. | Ref. |
Tertile 2 | 0.91 (0.55, 1.51) | 0.67 (0.40, 1.11) |
Tertile 3 | 0.91 (0.50, 1.65) | 0.57 (0.33, 0.97) |
Increase per 1 SD | 0.90 (0.70, 1.16) | 0.84 (0.63, 1.11) |
Incident prostate cancer#(in male participants) | ||
Tertile 1 | Ref. | Ref. |
Tertile 2 | 0.47 (0.24, 0.92) | 0.97 (0.49, 1.92) |
Tertile 3 | 0.68 (0.37, 1.24) | 1.11 (0.51, 2.42) |
Increase per 1 SD | 0.78 (0.60, 1.03) | 1.15 (0.82, 1.62) |
All-cause mortality┼ | ||
Tertile 1 | Ref. | Ref. |
Tertile 2 | 0.90 (0.74, 1.11) | 0.99 (0.80, 1.22) |
Tertile 3 | 1.14 (0.93, 1.41) | 1.17 (0.93, 1.47) |
Increase per 1 SD | 1.03 (0.94, 1.12) | 1.08 (0.98, 1.18) |
Cancer mortality┼ | ||
Tertile 1 | Ref. | Ref. |
Tertile 2 | 0.91 (0.69, 1.20) | 0.87 (0.66, 1.16) |
Tertile 3 | 0.87 (0.65, 1.16) | 0.97 (0.71, 1.31) |
Increase per 1 SD | 0.92 (0.81, 1.05) | 1.06 (0.94, 1.20) |
CVD mortality┼ | ||
Tertile 1 | Ref. | Ref. |
Tertile 2 | 0.87 (0.65, 1.16) | 1.04 (0.77, 1.40) |
Tertile 3 | 1.23 (0.92, 1.66) | 1.28 (0.93, 1.75) |
Increase per 1 SD | 1.04 (0.92, 1.17) | 1.08 (0.95, 1.22) |